Sandesh Seth

Insider Reports History

Reporting-owner location: New York, NY
Latest reporting-owner signature: /s/ Sandesh Seth
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Sandesh Seth

Form 4 holding Chief Executive Officer, Director

Actinium Pharmaceuticals, Inc.

Security class: Common Stock
Shares / value: 1,965,355
Estimated value: $1,926,047
Report date: 02 Sep 2026
Price: $0.9800
Ownership: Direct

Form 4 holding Chief Executive Officer, Director

Actinium Pharmaceuticals, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 1,130,400
Estimated value
Report date: 02 Sep 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Sandesh Seth

4 ATNM

Actinium Pharmaceuticals, Inc.

Report period: 02 Sep 2026
Transactions: 3
Transaction value: $0
Accepted by SEC: 04 Sep 2026, 17:00
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ATNM

Actinium Pharmaceuticals, Inc.

Report period: 18 Aug 2025
Transactions: 1
Transaction value: -$206,739
Accepted by SEC: 20 Aug 2025, 17:00
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ATNM

Actinium Pharmaceuticals, Inc.

Report period: 31 Mar 2025
Transactions: 8
Transaction value: $0
Accepted by SEC: 02 Apr 2025, 18:20
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ATNM

Actinium Pharmaceuticals, Inc.

Report period: 28 Dec 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 29 Dec 2023, 17:17
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ATNM

Actinium Pharmaceuticals, Inc.

Report period: 17 Aug 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 19 Aug 2022, 16:55
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ATNM

Actinium Pharmaceuticals, Inc.

Report period: 01 Jul 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 01 Jul 2022, 19:13
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ATNM

Actinium Pharmaceuticals, Inc.

Report period: 01 Sep 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 03 Sep 2021, 17:01
Role: Chief Executive Officer, Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .